ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08444
-0,11%
Bitcoin
67.646,36
-0,12%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) News

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OKYO
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/05/202413h00GlobeNewswire Inc.OKYO Pharma Announces Participation in May 2024 Investor ConferencesNASDAQ:OKYOOKYO Pharma Ltd
30/04/202413h00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)NASDAQ:OKYOOKYO Pharma Ltd
09/04/202401h00GlobeNewswire Inc.OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024NASDAQ:OKYOOKYO Pharma Ltd
02/04/202413h00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryNASDAQ:OKYOOKYO Pharma Ltd
22/03/202412h00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101NASDAQ:OKYOOKYO Pharma Ltd
21/03/202412h00GlobeNewswire Inc.OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialNASDAQ:OKYOOKYO Pharma Ltd
20/03/202412h00GlobeNewswire Inc.OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventNASDAQ:OKYOOKYO Pharma Ltd
09/02/202413h36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
09/02/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
09/02/202413h00GlobeNewswire Inc.OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
31/01/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
31/01/202413h00GlobeNewswire Inc.OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardNASDAQ:OKYOOKYO Pharma Ltd
08/01/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/01/202413h00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
05/01/202415h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
05/01/202415h30GlobeNewswire Inc.OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024NASDAQ:OKYOOKYO Pharma Ltd
21/12/202313h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
20/12/202323h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
18/12/202322h56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
04/12/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
04/12/202313h00GlobeNewswire Inc.OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol VisitNASDAQ:OKYOOKYO Pharma Ltd
29/11/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
01/11/202321h55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
31/10/202321h59Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
31/10/202312h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
31/10/202312h00GlobeNewswire Inc.OKYO Pharma Announces $5.84 Million Cash Raise and Payables ReductionNASDAQ:OKYOOKYO Pharma Ltd
10/10/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
09/10/202317h34InvestorsHub NewsWireOKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")NASDAQ:OKYOOKYO Pharma Ltd
09/10/202313h00GlobeNewswire Inc.OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)NASDAQ:OKYOOKYO Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:OKYO

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
USOTC
BASFY
BASF (QX)
PM
XAUUSD
Gold vs US Dollar
CCOM
US100
US Tech 100
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
GOOGL
Alphabet
TG
DTE
Deutsche Telekom
FX
EURUSD
Euro vs US Dollar
TG
RHM
Rheinmetall
DBI
TDXP
Tec DAX
FX
EURJPY
Euro vs Yen
NYSE
MCD
McDonalds
TG
CBK
Commerzbank
TG
D7G
Nel ASA
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten